CJC-1295 has one of the strongest published human clinical records of any wellness-market peptide, a Phase 2 trial that was discontinued after a participant death, and a December 2024 FDA advisory committee vote against allowing it into the regulated compounding system. The gap between the science and the regulatory verdict is where its current safety…
